Q4 2024 Earnings Call Transcript March 17, 2025 FibroGen, Inc. reports earnings inline with expectations. Reported EPS is $-0 ...

Achieved Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 ...

Thane Wettig; Interim Chief Executive Officer, Chief Commercial Officer; FibroGen Inc. David Delucia; Vice Presi ...

De novo antibody design has been one of the major challenges in AI-based drug discovery, requiring atomic-level precision to ...

Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 millionTransaction expected to close by ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected ...

Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close of sale of FibroGen China, cash runway exte ...

OBJECTIVES Thus, this study aimed to develop an in silico multi-epitope vaccine against Rickettsia. METHODS Eight proteins were previously identified as potential vaccine candidates through reverse ...

Schematic workflow to estimate de novo antibody sequences by the integration of cryoEM and LC-MS/MS data with Stitch. Figure 2. Determining de novo antibody sequences from cryoEM data with ModelAngelo ...